Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET

Company Participants

Andrew Guggenhime - President and Chief Financial Officer

Grant Pickering - Chief Executive Officer, Director and Founder

Jim Wassil - Executive Vice President and Chief Operating Officer

Conference Call Participants

Jason Gerberry - Bank of America

Roger Song - Jefferies

Dave Risinger - Leerink Partners

Umer Raffat - Evercore

Seamus Fernandez - Guggenheim

Louise Chen - Cantor Fitzgerald

Joseph Stringer - Needham

Operator

Good afternoon, everyone. My name is Bo and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full-Year 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period. [Operator Instructions] And just a reminder, today's call is being recorded.

Now at this time, I will turn things over to Mr. Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. Please go ahead, sir.

Andrew Guggenhime

Thank you, operator, and good afternoon, everyone. I'd like to welcome you to Vaxcyte's earnings conference call to discuss our 2023 results and to provide a business update. I'm joined today by our Chief Executive Officer, Grant Pickering; and our Executive Vice President and Chief Operating Officer, Jim Wassil.

Earlier this afternoon, we issued a news release announcing our results. Copies of this and our other news releases, latest corporate presentation and SEC filings can be found in the Investor & Media section of our website.

Before we begin, I'd like to remind you that during this call we'll be making certain forward-looking statements about Vaxcyte, which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements. For a discussion of the risks and uncertainties associated with these statements, please see our press release issued today, as well as our most recent filings with the SEC, including the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and any subsequent reports filed with the SEC.

With that, I'll turn the call over to Grant Pickering. Grant?

Grant Pickering

Thanks, Andrew, and all of you on the call and webcast, thank you for joining us today. 2023 was another remarkable year for Vaxcyte, officially marking our 10th year of thoughtful and methodical research and development by the entire Vaxcyte team and our partners. We are driven by our mission to prevent or treat infections caused by bacterial diseases, including invasive pneumococcal disease for IPD.